21st Feb 2007 16:06
More than 75 pharmaceutical, biotechnology and chemical companieshave licensed the new, open-technology MDL(R) Isentris(R) system toaddress common R&D challenges, Elsevier MDL has announced. Leadingresearch companies turning to the new-generation Isentris systeminclude more than half of Elsevier MDL's top 30 customers. £ The announcement came during a forum hosted by Elsevier MDL forresearch and IT executives from around the world to address strategiesand new informatics technology for reducing R&D timelines, cuttingcosts and improving productivity. £ "For more than a decade, almost every major pharmaceutical companyhas relied upon the current-standard, MDL(R) ISIS(R) technology intheir labs," said President and CEO Lars Barfod, Elsevier MDL. "Manycompanies are now seeing the potential to realize significantly betterresults from their operations by migrating to Isentris. The recentIsentris 2.0 release far surpasses ISIS and competitive systems interms of functionality, performance and lower cost of ownership." £ With Isentris, organizations are giving scientists easier accessto relevant data in the course of their normal workflows, and arefacilitating coordination of the tools and capabilities needed to makedecisions on that data. Isentris includes .NET controls for rapidlybuilding customized, easy-to-use research environments with powerfulscientific capabilities. £ "The growing migration to Isentris reflects a new era, an'Informatics 2.0' for scientists," said Dr. Trevor Heritage, SeniorVice President and Chief Scientific Officer, Elsevier MDL."Researchers have control to create and access the specific views ofdata they need to answer questions and test hypotheses immediately --without relying on IT support." £ In a case study cited in the executive forum, a Europeanpharmaceutical company that migrated to Isentris from ISIS praised thesystem's much improved integration and ease-of-use, and scientists'new ability to access biological assay data, chemistry and otherexperimental and calculated data as soon as it is created. £ An example of Isentris performance and cost-saving advantages isimproved operation over wide area networks (WAN) that connectgeographically remote labs. On a WAN, Isentris lets scientists performcommon tasks like browsing chemical records 15 times faster than ISIS,and retrieve searches two to three times faster. This speed makes WANconfigurations practical for many organizations with multi-siteoperations, which in turn offer a path to significant cost savings. £ More information about Isentris, including presentations from theexecutive roundtable session, white papers and case studies areavailable on www.mdl.com/executive. £ About Elsevier MDL £ Elsevier MDL provides informatics, database and workflow solutionsthat accelerate successful scientific R&D by improving the speed andquality of scientists' decision making. Researchers around the worlddepend on Elsevier MDL for innovative and reliable discoveryinformatics software solutions and services. For more information,visit www.mdl.com. £ MDL and Isentris are registered trademarks of MDL InformationSystems, Inc. ('Elsevier MDL') in the United States. All rightsreserved. All other trademarks mentioned in this document are theproperty of their respective owners. Copyright Business Wire 2007Related Shares:
Relx